Protein Engineering Market to Reach $3.15 Billion by 2035 at 14.1% CAGR | ATUM, Creative BioMart, Quantumzyme

The global protein engineering market, valued at USD 0.85 billion in 2025, will grow to USD 3.15 billion by 2035, advancing at a compound annual growth rate of 14.1% over the 2026 to 2035 forecast period. The market is already crossing the USD 0.96 billion mark in 2026, signaling strong near-term momentum. With more than 85 specialized companies active in the space and over 550 patents filed or granted in recent years, protein engineering has moved well beyond academic research into a commercially significant segment of the global biopharmaceutical supply chain.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/protein-design-and-engineering-market/request-sample.html

MARKET OVERVIEW
Protein engineering refers to the deliberate modification of protein structures through amino acid manipulation, enabling the development of therapeutic and diagnostic molecules with precisely defined properties. The technique underpins some of the most clinically significant drug classes available today, including monoclonal antibodies, therapeutic enzymes, peptide therapeutics, hormones, and protein-based vaccines. More than 55 protein-based therapies have already reached the commercial market, addressing conditions ranging from cancer and autoimmune disease to genetic disorders.

The commercial appeal of protein engineering extends beyond its scientific promise. Engineered proteins offer meaningful clinical advantages over small-molecule drugs: higher target specificity, lower toxicity, reduced hepatic metabolism, and improved safety profiles. These characteristics have made protein therapeutics a preferred tool for pharmaceutical companies pursuing precision medicine strategies. As a result, R&D activity in this segment has intensified steadily, drawing in both large biopharma firms and a growing ecosystem of specialized contract service providers.

Recent public and private investment confirms this trajectory. In March 2026, the Washington Research Foundation awarded a USD 7 million grant to the University of Washington Institute for Protein Design, targeting AI-enabled enzyme engineering for sustainable biomanufacturing. In February 2026, A-Alpha Bio entered a partnership with Novo Nordisk specifically to advance AI-driven protein engineering. A month earlier, Avenue Biosciences closed a USD 5.7 million funding round to scale its protein engineering platform. These developments reflect a broader pattern: capital is flowing into the intersection of protein science and computational biology at an accelerating rate.

KEY GROWTH DRIVERS
Rising demand for personalized medicines and biopharmaceuticals. Pharmaceutical companies are directing a growing share of their pipelines toward biologics, where customized protein design is a prerequisite. Monoclonal antibodies, therapeutic proteins, and biologics all require precise structural optimization to achieve desired efficacy and safety. As biopharmaceutical product development expands, so does the need for protein engineering expertise capable of delivering those customizations reliably and at scale.

Advances in directed evolution, CRISPR, and computational protein design. Three technological currents are converging to make protein engineering faster and more predictable. Directed evolution allows researchers to screen large protein libraries for desired traits. CRISPR-based gene editing enables precise modifications at the genomic level. Computational protein design, increasingly powered by artificial intelligence, allows scientists to predict accurate protein structures and identify functional variants before committing to costly wet-lab experiments. Together, these methods are reducing the time and capital required to produce viable protein candidates.

AI integration in protein structure prediction and engineering workflows. AI-assisted tools are now actively used to optimize protein engineering processes, improving the success rate of projects and reducing failure at later development stages. In March 2026, OpenProtein.AI partnered with Boehringer Ingelheim to integrate AI-driven protein design into antibody discovery workflows for oncology and immunology applications. Similarly, Abcam joined the LIGAN-AI project under Innovative Health Initiatives in January 2026, contributing its recombinant protein engineering expertise to an open-science drug discovery consortium.

Outsourcing growth and expanding CRO capabilities. Developing engineered proteins demands specialized infrastructure, high-throughput screening platforms, and deep technical expertise that most pharmaceutical companies prefer not to replicate in-house. This has driven a structural shift toward outsourcing protein engineering activities to contract research and manufacturing organizations. Over 85 protein engineering companies globally now offer these services, and the CRO sub-segment is growing at a CAGR of 14.4% through 2035, reflecting a durable commercial model built on pharmaceutical outsourcing trends.

Proliferating patent activity signaling sustained innovation. Over 550 patents related to protein design and engineering techniques have been filed or granted in recent years, a figure that directly measures the pace at which new intellectual property is entering this space. High patent volume indicates active competition among research institutions and commercial players to stake claims on next-generation engineering methods. This level of IP activity typically precedes commercial product launches and signals that the pipeline of engineered therapeutics in development remains deep.

MARKET SEGMENTATION
The protein engineering market segments across approach type, protein type, application, end user, and geography. By engineering approach, rational designing holds the largest share and will account for 53% of total revenue by 2035, growing at a CAGR of 15%. Its dominance reflects the growing use of computational modeling in antibody development and enzyme engineering, where precision at the design stage reduces downstream failure rates. Directed evolution remains widely adopted, particularly for applications demanding high-throughput screening across large protein libraries.

By protein type, antibodies account for 48% of projected 2035 market share, driven by the continued clinical success of monoclonal antibodies in oncology. Vaccines represent the fastest-growing protein sub-segment at a 14.8% CAGR, as industry leaders direct research toward protein-based infectious disease interventions. By application, therapeutics commands 78% of projected 2035 revenue and will grow at a 14.4% CAGR, while diagnostics provides a complementary growth channel. Among end users, pharma and biotech firms hold 61% of the market, with CROs expanding at a CAGR of 14.4% as outsourcing accelerates.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/protein-design-and-engineering-market/request-quote.html

REGIONAL INSIGHTS
North America leads the global protein engineering market and will hold 32% of total market share by 2035. The region's position reflects a high concentration of pharmaceutical and biotechnology companies, an active partnership and M&A environment, and a well-developed contract services ecosystem. Nearly 50% of all protein engineering companies globally are headquartered in North America, and approximately 43% of all partnerships and collaborations in this space have involved North American parties.

Asia-Pacific is the fastest-growing regional market, with a projected CAGR of 15% through 2035. Expanding biopharmaceutical manufacturing capacity, growing government investment in life sciences, and rising domestic demand for advanced therapeutics are each contributing to regional growth. Europe maintains a significant presence as well, supported by initiatives such as the IHI-backed LIGAN-AI project, which brought together 18 partners, including Abcam, to advance AI-driven drug discovery using protein engineering as a foundational capability.

COMPETITIVE LANDSCAPE
Key companies profiled in the protein engineering market include ATUM, Creative BioMart, Creative Biostructure, Creative Enzymes, Absolute Antibody, EUCODIS Bioscience, Fusion Antibodies, Innovagen, ZYMVOL, Averring Biotech, EnzymeWorks, GeNext Genomics, and Quantumzyme, among more than 85 active service providers globally.

The market is highly fragmented. Established players and new entrants co-exist across small, mid-sized, and large company categories, and no single provider holds dominant share. Competition centers primarily on service breadth, technical specialization, and the depth of engineering platforms on offer. Approximately 30% of active players provide services spanning both therapeutics and diagnostics, while the majority focus on antibody engineering. Companies are steadily expanding existing capabilities to serve a client base that increasingly wants end-to-end support from protein design through characterization, purification, and clinical-stage production. Strategic alliances and licensing agreements are becoming a key competitive tool, with a notable cluster of deals signed in 2021 and activity continuing through 2026.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/protein-design-and-engineering-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.